Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice

@article{Gardiner2006PharmacogeneticsDE,
  title={Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice},
  author={Sharon J. Gardiner and Evan James Begg},
  journal={Pharmacological Reviews},
  year={2006},
  volume={58},
  pages={521 - 590}
}
The application of pharmacogenetics holds great promise for individualized therapy. However, it has little clinical reality at present, despite many claims. The main problem is that the evidence base supporting genetic testing before therapy is weak. The pharmacology of the drugs subject to inherited variability in metabolism is often complex. Few have simple or single pathways of elimination. Some have active metabolites or enantiomers with different activities and pathways of elimination… 

Figures and Tables from this paper

Genetic and Epigenetic Factors Affecting Cytochrome P450 Phenotype and Their Clinical Relevance

During drug development, it is important to consider pharmacogenetic variation which could explain or even prevent discarding a drug candidate if appropriate genetic reasons are identified or when lack of response/occurrence of ADRs (adverse drug reactions) in drug therapy is experienced.

Toward the Safer and More Effective Use of Prescription Drugs: Pharmacogenetics

There are several gene variants that are known to influence the pharmacokinetics of many prescribed drugs, and these tests, while limited, can help guide dosing strategies for some patients, thereby reducing the frequency of adverse drug reactions.

Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects

This review examines the genetically variable CYP450-mediated metabolism of a number of serotonin-active drugs that are often implicated in cases of serotonin toxicity, to assess the impact of pharmacogenetics on drug metabolism, response, interactions and adverse effects.

Genetic and Epigenetic Factors Affecting Cytochrome P 450 Phenotype and Their Clinical Relevance

During drug development, it is important to consider pharmacogenetic variation which could explain or even prevent discarding a drug candidate if appropriate genetic reasons are identified or when lack of response/occurrence of ADRs (adverse drug reactions) in drug therapy is experienced.

Are Pharmacogenetics and Pharmacogenomics Important for Critically III Patients

Drugs are administered to patients using dosing regimens established from animal data, clinical trials, and population studies. However, there may be enormous variation in dose requirement, efficacy,

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice

  • V. Manolopoulos
  • Medicine, Biology
    Clinical chemistry and laboratory medicine
  • 2007
The thesis is that pharmacogenomics is already a reality in clinical practice and is bound to continue gaining acceptance by clinicians in the coming years.

GENETICS/GENOMICS AND DRUG EFFECTS

  • F. Heller
  • Biology, Medicine
    Acta clinica Belgica
  • 2013
Genetics and genomics will probably help to personalise medicine by conferring to the clinician the possibility of giving the right drug to the right patient and by this way improving efficacy and safety of medications.

Pharmacogenetics of drug-metabolizing enzymes: the prodrug hypothesis.

The hypothesis that prodrugs are over-represented in drugs that may be affected by genetic polymorphisms is proposed and may assist in the efforts to advance the field.

The role of pharmacogenetics in nonmalignant gastrointestinal diseases

  • M. Camilleri
  • Medicine, Biology
    Nature Reviews Gastroenterology &Hepatology
  • 2012
Genetic variants that have the greatest effect on the management of patients with IBD involve the metabolism of thiopurines, and pharmacogenetics could have a beneficial role in enabling pharmacotherapy for nonmalignant gastrointestinal diseases to be targeted to the individual patient.
...

References

SHOWING 1-10 OF 1,095 REFERENCES

Inheritance and drug response.

The underlying message is that inherited variations in drug effect are common and that some tests that incorporate pharmacogenetics into clinical practice are now available, with many more to follow.

Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice?

It is widely claimed that pharmacogenetics may form the basis of ‘personalized medicine’. We sought to determine the current utilization of pharmacogenetic testing for drug metabolizing enzymes

The future prospects of pharmacogenetics in oral anticoagulation therapy.

Coumarins are the mainstay of oral anticoagulation for the treatment and prophylaxis of thromboembolic disorders. They have a narrow therapeutic index and regular monitoring is therefore required to

Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication

  • I. Cascorbi
  • Biology
    European journal of clinical investigation
  • 2003
Since there is evidence that deteriorated drug elimination partly accounts for drug side‐effects, CYP2D6 genotyping could contribute to an individualized and therefore optimized drug therapy.

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

Combinations of polymorphisms in pharmacokinetic and pharmacodynamic pathways of relevance might contribute to identify genotypes associated with best and worst responders and they may also identify susceptibility to adverse drug reactions.

Pharmacogenetics of Warfarin Elimination and its Clinical Implications

Data indicate that the CYP2C9*3 allele may be associated with retarded elimination of (S)-warfarin and the resulting clinical effects, however, relationships between CYP 2C9 genotype, enzyme activity, metabolism of probe substrates, dosage requirements and bleeding complications should be interpreted with caution, and further studies are required.

Metabolism and pharmacokinetics of phenelzine: lack of evidence for acetylation pathway in humans.

It is indicated that N-acetylation of phenelzine is not a significant metabolic pathway in humans, which helps explain recent clinical studies that failed to find an association between acetylation phenotype and clinical effects of phenElzine.

Clinical Consequences of Cytochrome P450 2C9 Polymorphisms

Cancer pharmacogenomics: achievements in basic research

In this review, genetic polymorphisms of CYP enzymes and their clinical relevance in cancer chemotherapy are discussed.
...